N
CRVS icon

Nuveen’s Corvus Pharmaceuticals CRVS Stock Holding History

Nuveen’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.18M Buy
149,126
+81,062
+119% +$1.29M ﹤0.01% 2245
2025
Q4 		$524K Hold
68,064
– – ﹤0.01% 2852
2025
Q3 		$502K Hold
68,064
– – ﹤0.01% 2891
2025
Q2 		$272K Buy
+68,064
New +$248K ﹤0.01% 3085

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Nuveen's CRVS Position: Q1 2026 in Review

Nuveen increased its Corvus Pharmaceuticals (CRVS) stake by 119% in Q1 2026, buying an estimated $1.29M and bringing the position to 149,126 shares worth $2.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2245.

Nuveen first reported a position in CRVS in Q2 2025 and has held it in 4 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Nuveen held 149,126 shares of Corvus Pharmaceuticals worth $2.18M as of Q1 2026.
  • Nuveen bought 81,062 Corvus Pharmaceuticals shares in Q1 2026, an estimated $1.29M.
  • Corvus Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2245 holding.
  • Nuveen first reported a position in Corvus Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.